Trial-Results center  
Clinical trial results database Feedback    Home

This trial is included in the following systematic reviews and meta-analyses:

hypertension - strategy - diabetic patients  

hypertension - strategy - all type of patients  


Related trials

Cardio-Sis, 2009 - more intensive blood pressure lowering strategie vs less intensive blood pressure lowering strategie

ACCORD blood pressure, 2008 - more intensive blood pressure lowering strategie vs less intensive blood pressure lowering strategie

REIN-2, 2005 - more intensive blood pressure lowering strategie vs less intensive blood pressure lowering strategie

AASK, 2002 - more intensive blood pressure lowering strategie vs less intensive blood pressure lowering strategie

ABCD (N), 2002 - more intensive blood pressure lowering strategie vs less intensive blood pressure lowering strategie

ABCD (H), 2000 - more intensive blood pressure lowering strategie vs less intensive blood pressure lowering strategie

Toto, 1995 - more intensive blood pressure lowering strategie vs less intensive blood pressure lowering strategie

HOT, 1994 - more intensive blood pressure lowering strategie vs less intensive blood pressure lowering strategie

MDRD, 1994 - more intensive blood pressure lowering strategie vs less intensive blood pressure lowering strategie



See also:

  • All hypertension clinical trials
  • All clinical trials of strategy
  • All clinical trials of more intensive blood pressure lowering strategie
    		•  

    ABCD (H) study, 2000

    Treatments

    Studied treatment intensive treatment with a diastolic blood pressure goal of 75 mmHg
    Control treatment moderate treatment with a diastolic blood pressure goal of 80-89 mmHg
    Remarks factorial design: nisoldipine or enalapril as the initial antihypertensive
    Treatments description
    Achieved systolic blood 132/138 
    Achieved diastolic blood pressure 78/86 

    Patients

    Patients diabetes patients with DBP >=90 mmHg
    Exclusion criteria myocardial infarction or a cerebrovascular accident within the previous 6 months, had coronary artery bypass surgery within the previous 3 months, had unstable angina pectoris within the previous 6 months, had congestive heart failure NYHA class III or IV, demonstrated an absolute need for ACE inhibitors or CCB, and/or had a serum creatinine level > 3 mg/dl.

    Method and design

    Randomized effectives 237 / 233 (studied vs. control)
    Design Parallel groups
    Blinding open
    Follow-up duration 5 year


    Results

    Endpoint Studied treat.
    n/N     Control treat.
    n/N     Graph RR [95% CI]

    Cardiovascular death

    6 / 237
         11 / 233
         0,54 [0,20;1,43]

    myocardial infarction (fatal and non fatal)

    16 / 237
         14 / 233
         classic 1,12 [0,56;2,25]

    Heart failure

    9 / 237
         9 / 233
         classic 0,98 [0,40;2,43]

    All cause death

    10 / 237
         22 / 233
         0,45 [0,22;0,92]

    non cardiovascular death

    4 / 237
         11 / 233
         0,36 [0,12;1,11]

    stroke (fatal and non fatal)

    9 / 237
         9 / 233
         classic 0,98 [0,40;2,43]

    Major cardiovascular events

    36 / 237
         39 / 233
         0,91 [0,60;1,37]     0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial    		 Ref
    Studied treat. Control treat.
    Cardiovascular death 6 / 237 (2,5%) 11 / 233 (4,7%) 0,54 [0,20;1,43]   11040 
    myocardial infarction (fatal and non fatal) 16 / 237 (6,8%) 14 / 233 (6,0%) 1,12 [0,56;2,25]   11040 
    stroke (fatal and non fatal) 9 / 237 (3,8%) 9 / 233 (3,9%) 0,98 [0,40;2,43]   11040 
    Major cardiovascular events 36 / 237 (15,2%) 39 / 233 (16,7%) 0,91 [0,60;1,37]   11040 
    All cause death 10 / 237 (4,2%) 22 / 233 (9,4%) 0,45 [0,22;0,92]   11040 
    non cardiovascular death 4 / 237 (1,7%) 11 / 233 (4,7%) 0,36 [0,12;1,11]   11040 
    Heart failure 9 / 237 (3,8%) 9 / 233 (3,9%) 0,98 [0,40;2,43]   11040 
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:
  • 11040: Arguedas JA, Perez MI, Wright JMTreatment blood pressure targets for hypertension.Cochrane Database Syst Rev 2009;:CD004349

    • Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    Cardiovascular death 2,53% 4,72% -21,9‰
    myocardial infarction (fatal and non fatal) 6,75% 6,01% 7,4‰
    stroke (fatal and non fatal) 3,80% 3,86% -0,7‰
    Major cardiovascular events 15,19% 16,74% -15,5‰
    All cause death 4,22% 9,44% -52,2‰
    non cardiovascular death 1,69% 4,72% -30,3‰
    Heart failure 3,80% 3,86% -0,7‰


    Reference(s)

    Trials register # NA
    • Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes.. Diabetes Care 2000;23 Suppl 2:B54-64
      Pubmed | Hubmed | Fulltext

    (c) 2004-2010 TrialResults-center - All Rights Reserved

    Tweet this  |  notify a friend